How Alnylam’s gene-silencing technology nips disease in the bud

Alnylam’s ingenious technology can penetrate our tiniest cells to tinker with the genes that cause disease. Douglas Brodie of the Edinburgh Worldwide Investment Trust describes how the US biopharma company is poised to apply its gene silencing technology to some of the world’s biggest killer diseases. Capital at risk.

Read more >


Editor's Picks